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ABSTRACT
2- or 4-Substituted 3-N-benzyltriazolylmethyl-13a-oestrone derivatives were synthesised via bromination of
ring A and subsequent microwave-assisted, Pd-catalysed C(sp2)–P couplings. The antiproliferative activities
of the newly synthesised brominated and phosphonated compounds against a panel of human cancer
cell lines (A2780, MCF-7, MDA-MB 231) were investigated by means of MTT assays. The most potent com-
pound, the 3-N-benzyltriazolylmethyl-4-bromo-13a-oestrone derivative exerted substantial selective cell
growth-inhibitory activity against A2780 cell line with a submicromolar IC50 value. Computational calcula-
tions reveal strong interactions of the 4-bromo derivative with both colchicine and taxoid binding sites of
tubulin. Disturbance of tubulin function has been confirmed by photometric polymerisation assay.
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The development of anticancer agents is often based on synthetic
modifications of endogenous compounds1. However, this
approach might be limited by the retained original biological
activity of the biomolecule. This happens in the case of antiproli-
ferative drug candidates based on sex hormones. Certain oestrone
derivatives efficiently suppress the growth of different tumour
cells, but their retained oestrogenic behaviour limits their applica-
tion. Nevertheless, directed chemical modifications of the estrane
core may lead to the reduction of oestrogenic action. The inver-
sion of configuration at C-13 or opening of ring D results in core-
modified oestrone derivatives with complete loss of oestrogenic
activity2–5. Accordingly, 13a-oestrone and D-secoestrone are prom-
ising scaffolds for the development of antitumoral oestrone deriv-
atives lacking hormonal side effects. Literature reveals certain
potent anticancer oestrone derivatives, but their mechanism of
action is often unclarified1. There exist candidates acting via inhib-
ition of oestrogen biosynthesis; however, the majority of this com-
pound group target other objects, including transporter proteins
or tubulin. Microtubules (MTs) consist of a- and b-tubulin hetero-
dimers that play key role in cell division6. Drugs that interfere
with tubulin polymerisation/depolymerisation dynamics might
lead to suppression of the cell growth7–9. Drugs that target the
MT might be divided into two groups. MT destabilising agents
(MDAs) prevent polymerisation of tubulin and promote depoly-
merisation, whereas MT stabilising agents (MSAs) promote poly-
merisation of tubulin and stabilise the polymer, preventing
depolymerisation. There exist six binding sites on tubulin poly-
mer7,10,11. MSAs, in general, bind reversibly to the taxoid binding
site. Several antitubulin agents targeting vinca alkaloid or taxane
sites (TBS) have been approved by Food and Drug Administration
(FDA), but their application is limited due to their inefficiency
against multidrug resistant (MDR) cells. On the other hand, colchi-
cine site-binding candidates (CBS) are often still active against
MDR cells, too. Combrestatin A-4 (CA-4) is a colchicine site-binding
nanomolar antitubulin agent, arresting the cells in metaphase.
Moreover, it is assigned as a potent vascular disrupting agent. It is
of note that certain CA-4 derivatives are in clinical trials as chemo-
therapeutic agents. X-ray crystal structures of tubulin show that
there are three zones and a bridge in this binding site. The typical
colchicine site-binding agent consists of two aryl rings and a
bridge, which determine the relative orientation of the rings11.
According to literature reports, replacement of methoxy groups
with halogens and introduction of a triazole or tetrazole ring
instead of an ethylene bridge might be a powerful strategy in the
development of more effective antitubulin CA-4 derivatives
(Figure 1)12. The triazole heterocycle is widely used in drug devel-
opment according to its favourable characteristics. It might
enhance the stability against metabolic degradation and the H-
bonding ability. Additionally, this heterocyclic ring is an excellent
mimetic of a peptide bond13.
We have recently synthesised steroidal triazoles via the trans-
formation of the phenolic OH group of the core-modified D-
secoestrone scaffold14. 13a and 13b epimers of D-seco derivatives
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were used as starting compounds. The triazole moiety was intro-
duced onto C-3-O via CuAAC reaction of 3-(prop-2-inyloxy) deriva-
tives with benzyl azides. The evaluation of cell growth-inhibitory
properties of 3-[(1-benzyl-1,2,3-triazol-4-yl)methoxy]-D-secoes-
trones against certain cervical, breast, and ovarian cancer cells was
carried out. The determination of structure–activity relationship
revealed that the antiproliferative effect greatly depends on both
the orientation of the angular methyl group and the nature and
size of the para substituent of the benzyl group. 13b Derivatives
seemed to be generally more active, but a 13a compound dis-
played a substantial effect. The most potent compound displayed
an IC50 value in the low micromolar range. It was proved that the
presence of the phenolic OH group is disadvantageous concerning
the desired antiproliferative activity, but the introduction of a ben-
zyl or, in particular, a 1-benzyl-1,2,3-triazol-4-yl moiety onto C-3-O
leads to marked activity improvements. D-Secoestrone triazole 3
(Figure 2) was subjected to additional biological investigations in
order to shed light on its mechanism of action15. The immuno-
cytochemical flow cytometric analysis alluded to a cell cycle arrest
at G2/M in HeLa cells with cell accumulation in the M phase. It
was proved by an in vitro tubulin polymerisation assay that com-
pound 3 significantly increases the maximum rate of microtubule
formation. The antimigratory experiment showed that this triazole
(3) inhibits the migration and invasion of HeLa cells. Based on
these encouraging results, the 1-benzyl-1,2,3-triazol-4-yl moiety
was introduced onto C-3-O of 13a-oestrone bearing an intact ring
D16. Our concept was to improve the one-micromolar IC50 value
of the best D-secoestrone triazole by synthesising new com-
pounds bearing the same structural element at C-3-O, but on the
other promising, hormonally inactive 13a-oestrone scaffold. The
most potent compound (4a) was that without any additional para
substituent with IC50 values in the submicromolar range. These
results highlight the importance of 13a-oestrone as a scaffold and
the 3-N-benzyltriazolylmethyl moiety as a key element in the
development of potent oestrone-based antiproliferative agents
lacking oestrogenic action.
In recent years, we turned our attention on the synthesis of novel
2- or 4-substituted 13a-oestrone derivatives. First ring A halogena-
tions and then Pd-catalysed C–P cross-coupling reactions were car-
ried out17,18. Hirao reaction is widely used for the synthesis of
arylphosphonates from aryl halides19. Variations of the reaction have
been described under traditional thermal conditions or microwave-
irradiation20–22. Dialkyl phosphites are usually used as the reagents,
Pd(PPh3)4 as the catalyst and Et3N as the base. Our certain novel
halo and phosphono 13a-oestrone derivatives displayed outstanding
inhibitory activities against enzymes (steroid sulfatase, STS and 17b-
hydroxysteroid dehydrogenase 1, 17b-HSD1) involved in oestrogen
biosynthesis. Concerning oestrogen-dependent diseases, the suppres-
sion of local oestrogen production might serve as an effective ther-
apy. This strategy might be intensified by the inhibition of
polypeptides transporting organic anions (OATPs), which are able to
transport oestrone-3-sulfate (E1S) into cells23,24. The desulphation of
E1S and the stereospecific reduction of E1 result in E2 with a marked
cell proliferative potential. Certain OATPs, known as E1S transporters,
are overexpressed, among others, in breast and ovarian tumours. It is
of note that both 2-bromo- and 4-bromo-13a-oestrone derivatives (5
and 6, Figure 3), synthesised recently, exerted outstanding 17b-HSD1
inhibition (IC50 ¼  1mM). Compound 6, however, displayed dual
STS and 17b-HSD1 inhibition. Additionally, 3-hydroxy-2-phosphonate
7 proved to be dual 17b-HSD1 and OATP2B1 inhibitor with IC50 val-
ues of 1–2mM, whereas its 3-benzyloxy counterpart (8) exhibited
selective OATP2B1 inhibition with IC50 ¼ 0.2mM (Figure 3)18.
Based on our above-mentioned structure–activity results
obtained in antiproliferative, tubulin polymerisation and OATP2B1
transport assays, our aim in the present study was to combine the
key structural elements (highlighted in blue, green, and red in
Figures 2 and 3) to get potent antiproliferative compounds. Here
we disclose the synthesis of 3-N-benzyltriazolylmethyl-13a-oes-
trone derivatives brominated or phosphonated at C-2 or C-4.
2. Results
2.1. Chemistry
The synthesis of 3-N-benzyltriazolylmethyl-13a-oestrone derivatives
substituted at C-2 or C-4 was started with the propargylation of
13a-oestrone 9 (Scheme 1). The terminal alkyne function was
introduced via our method established earlier16 using propargyl
bromide as the reagent. The resulting 3-(prop-2-inyloxy) com-
pound (10) was subjected to CuAAC reaction with benzyl azides
differing in their para substituent (R¼H or t-Bu). The click reac-
tions afforded the desired triazolyl derivatives (4a and 4b) in high
yields. The next transformation was the bromination of com-
pounds 4a and 4b. Electrophilic substitutions were carried out
with 1 equiv. of N-bromosuccinimide as a brominating agent.
Halogenations occurred in ortho positions relative to the C-3-O
function, yielding the two regioisomers in a ratio of 11:12¼ 2:1.
Bromo derivatives (11a,b or 12a,b) were subjected to Pd-catalysed
reactions with diethyl phosphite or diphenylphosphine oxide as
coupling partners. Microwave-assisted Hirao couplings afforded
new 2- or 4-phosphonated 3-N-benzyltriazolylmethyl-13a-oestrone
derivatives (13–15) in excellent yields. The structures of the newly
synthesised bromides and phosphonates (11–15) were deduced
from 1H and 13C NMR spectra.
2.2. Antiproliferative activities
The new compounds (11–15) were evaluated for their cell
growth-inhibitory action against an ovarian (A2780) and two
breast (MCF-7 and MDA-MB-231) human adherent cancer cell
lines. As a general tendency, ovarian cell line proved to be more
sensitive for the tested agents than the utilised breast cancers.
Certain newly synthesised derivatives exhibited substantial sub- or
low-micromolar antiproliferative potentials (Table 1). Bromo deriv-
atives (11 and 12) did not influence the growth of the tumour
cells, except compound 12a, which inhibited the proliferation of
A2780 cells with a submicromolar IC50 value. This test compound
displayed substantially higher IC50 values against the two other
cell lines. Derivatives 13b and 14a proved to be the most potent
in the phosphonate compound group with IC50 values in the low
micromolar range against all tested cell lines, which are compar-
able to those of reference agent cisplatin. Phosphonates exhibited
a similar level of potency against MCF-7 and MDA-MB-231 cell
lines. The only exception is compound 15b, which did not exert
considerable growth inhibitory action against MDA-MB-231 cells.
The cancer selectivity of compound 12a was tested by means of
the MTT assay using the non-cancerous mouse embryo fibroblast














X = Br, I
CA-4 (1) CA-4T (2)
Figure 1. Structures of combrestatin A-4 and its tetrazolyl derivative.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 59
modest inhibition of cell growth (28.73 ± 1.26% and 37.94 ± 0.75%
in 10 and 30mM, respectively) indicating the cancer selective prop-
erty of the determined antiproliferative action.
2.3. Tubulin polymerisation assay
Previously, D-secoestrone triazole (3) was proved to significantly
increase maximum rate of tubulin polymerisation15. Based on
structural similarity between compound 3 and the newly synthes-
ised 12a owing the lowest IC50 value against ovarian cancer cell
line A2780, 12a was supposed to influence microtubule formation.
To demonstrate our hypothesis, 12a was subjected to a cell-free,
in vitro tubulin polymerisation assay in two different concentra-
tions (125 and 250mM). The calculated maximum rate of tubulin
polymerisation was increased by our test compound which was
significant when 12a was added in 250 mM concentration to the
reaction mixture (Figure 4). Paclitaxel, the positive control agent
recommended by the manufacturer, evoked a threefold increase
in Vmax (Figure 4).
2.4. Computational simulations
First, docking studies have been performed for the newly syn-
thesised most potent antiproliferative compound 12a and for
secosteroid 3 selected as a reference compound. Two potential
binding sites, CBS and TBS, have been chosen on the tubulin
polymer. MD investigations have been performed starting from
the best docking poses of the compounds investigated. We
found that the binding positions were stable for both com-
pounds in both binding sites as they are presented by RMSD
calculations for the ligands [see Figure S1(A–D) in
Supplementary Materials]. Different MMGBSA binding energies
collected in Table 2 clearly show that both compounds can
bind to the regarded binding sites.
3. Discussion
3.1. Chemistry
The aim of the present work was to synthesise new 13a-oestrone
derivatives as potent antiproliferative agents against human can-
cer cell lines of reproductive origin. Our strategy included the
combination of structural elements of our promising antiprolifera-
tive or enzyme inhibitor compounds synthesised recently. Ring A
was chosen as the subject for transformations and positions C-2,
C-3, and C-4 were aimed to modify. Concerning the feasibility of
the planned transformations, the order of the reaction steps
seemed to be crucial. The activating behaviour of the phenolic
OH group enables fast and effective bromination of the aromatic
ring; however, the regio- and chemoselectivity is very low. To
enhance the selectivity, first the 3-OH group was etherified. We
have recently published that bromination of 3-O-methyl-13a-oes-
trone with 1 equiv. of NBS in dichloromethane results in a mixture
of 2- and 4-bromo regioisomers in a ratio of 1:317. Now we carried
out the etherification of the phenolic OH group with a dual pur-
pose: to get the two desired monobromo compounds regioselec-
tively in the next step, and to introduce a terminal alkyne
function onto C-3-O. We chose propargyl bromide as the reagent
and performed the reaction under the conditions established ear-
lier. The resulting phenolic ether (10) was suitable for the next
bromination step, but the addition reactions on the terminal
alkyne moiety had to be avoided. That is why we continued the
sequence with the CuAAC reaction of the propargyl derivative
(10) with two different benzyl azides (R¼H or t-Bu). Azide
reagents were selected based on the cell growth-inhibitory results
of 3-N-benzyltriazolylmethyl-13a-oestrone derivatives synthesised
and investigated earlier16. It has been established recently, that
compound 4a displayed outstanding antiproliferative action
against certain cancer cell lines; however, its para-t-Bu counterpart
4b did not influence cell growth markedly16. In this study, CuAAC
reactions were performed using CuI as catalyst and PPh3 as an
accelerating phosphine ligand. The desired triazoles (4a and 4b)
were formed in excellent yields. The CuAAC reactions were fol-
lowed by the bromination of the 3-N-benzyltriazolylmethyl com-
pounds (4a and 4b) with 1 equiv. of NBS in dichloromethane.
Electrophilic brominations furnished the two ortho regioisomers in
a ratio of 8:9¼ 2:1 in high yields. Interestingly, regioselectivity of
the bromination depends markedly on the nature and size of the
C-3-O function. The difference in regioisomeric ratios compared to
those of 3-O-Me derivatives might be explained by the steric hin-
drance of a more bulky 3-O substituent in 3-N-benzyltriazolyl-
methyl compounds 4a and 4b. In the last step, the 2- and 4-
bromo regioisomers were subjected to Hirao couplings. In our ear-
lier study, microwave-assisted conditions for the transformations
of 2- and 4-bromo-3-O-mehyl and 3-O-benzyl derivatives
involved 10mol% Pd(PPh3)4 as a catalyst, 1.3 equiv. of phosphite
or phosphine oxide, and 3 equiv. K2CO3 in toluene
18. The reaction
time and temperature depended on the nature of the 3-O



























Figure 3. Structures of potent 17b-HSD1 and OATP2B1 inhibitors.
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substituent. The transformations of 3-O-benzyl ethers required a
more apolar solvent (toluene instead of acetonitrile) and harsher
reaction conditions (150 C, 30min). Based on these experiences,
we performed the present couplings in toluene at 150 C, under
microwave irradiation for 30min. These conditions proved to be
Table 1. Antiproliferative properties of the synthesised compounds
Comp. Conc. (mM)
Inhibition (%) ± SEM [calculated IC50]
a
A2780 MDA- MB-231 MCF-7
11a 10 44.87 ± 0.09 47.49 ± 1.21 29.06 ± 1.42
30 52.00 ± 0.80 38.18 ± 2.78 36.49 ± 1.22
[21.51]
11b 10 30.18 ± 2.35 24.39 ± 2.20 –b
–30 33.94 ± 2.70 23.92 ± 1.07
12a 10 93.16 ± 0.47 52.94 ± 1.32 41.98 ± 0.97
30 95.43 ± 0.42 53.81 ± 2.43 52.50 ± 0.94
[0.55] [8.80] [12.69]
12b 10 46.93 ± 1.75 – 23.46 ± 1.03
30 54.72 ± 0.70 – 29.19 ± 2.94
[18.34]
13a 10 29.53 ± 1.86 – –
30 90.85 ± 0.40 35.95 ± 3.17 43.54 ± 2.63
[13.52]
13b 10 95.61 ± 0.59 57.03 ± 2.58 73.99 ± 1.88
30 99.73 ± 0.21 98.93 ± 0.20 95.52 ± 0.23
[2.95] [9.51] [6.59]
14a 10 95.97 ± 1.28 81.95 ± 2.49 66.93 ± 1.46
30 98.06 ± 0.89 98.52 ± 0.10 92.52 ± 1.08
[4.87] [7.13] [8.38]
14b 10 85.52 ± 0.64 46.57 ± 1.21 77.87 ± 0.66
30 95.82 ± 0.12 71.28 ± 1.23 90.69 ± 0.18
[5.07] [13.64] [7.16]
15a 10 79.93 ± 1.08 25.67 ± 1.76 42.44 ± 2.94
30 99.50 ± 0.03 96.87 ± 0.28 91.04 ± 1.49
[5.91] [13.15] [11.39]
15b 10 46.25 ± 1.27 – 30.14 ± 1.53
30 92.05 ± 0.86 34.79 ± 2.20 77.45 ± 1.56
[9.96]
Cisplatin 83.57 ± 1.21 67.51 ± 1.01 53.03 ± 2.29
95.02 ± 0.28 87.75 ± 1.10 86.90 ± 1.24
[1.30] [3.70] [5.78]
aMean value from two independent measurements with five parallel wells;
standard deviation <20%.
bInhibition values <20% are not presented.


















































Figure 4. Effects of 12a and 10mM paclitaxel on the calculated maximum reac-
tion rate (Vmax) of in vitro microtubule formation. Control: untreated samples. The
experiment was performed in two parallels and the measurements were repeated
twice. Each bar denotes the mean±SEM, n¼ 4. ns,  and indicate p> 0.05,
p< 0.05 and p< 0.001, respectively, compared with the control values.
Table 2. MMGBSA binding energies (in kcal/mol) of compound 3 and 12a in
the CBS and TBS. Standard deviations of calculations are presented in
parenthesis.
Compd. CBS TBS
3 55.8 (8.3) 58.8 (7.1)














































Y = OEt: 13, 15
Y = Ph: 14
Scheme 1. Synthesis of 2-substituted 3-N-benzyltriazolylmethyl-13a-oestrone derivatives.
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excellent for the effective synthesis of the desired phosphonates
(13a,b; 14a,b, and 15a), except for that of a 4-bromo derivative
bearing a 40-t-Bu substituent (15b). This coupling required longer
irradiation (150 C, 1 h), which might be attributed to
steric factors.
3.2. Determination of the antiproliferative activities
We described earlier that triazole 4a exerted outstanding
inhibitory activities against A2780 and MCF-7 cell lines in the
range of IC50 ¼ 0.5–0.6 mM. However, 4b, its 40-t-Bu counterpart
did not have marked influence on the growth of the tested cell
lines. Regarding the substantial difference in the antiprolifera-
tive potential of 4a and 4b, these two compounds have been
selected for further transformations. Besides testing the newly
synthesised compounds on A2780 (ovarian carcinoma) and
MCF-7 (breast adenocarcinoma, expressing the oestrogen, pro-
gesterone, and androgen receptors), an additional cell line, the
triple-negative breast carcinoma MDA-MB-231, was also
included in our study. Based on the present results obtained
for the phosphonates (Table 1), it can be stated, that this type
of modification did not improve the high potency of parent
compound 4a. The cell growth-inhibitory potential of the phos-
phonates is far behind to that of unsubstituted 4a. The low
micromolar IC50 values of the phosphonates (13b, 14a,b, and
15a) reflect their moderate antiproliferative potential.
Interestingly, phosphonates influenced the growth of A2780
cells most. Considering the two breast cancer cell lines with dif-
ferent receptorial status, no significant difference in growth-
inhibitory activities have been observed. However, two com-
pounds (12a and 14a) proved to be more potent against the
triple-negative MDA-MB-231 line. The presented pharmaco-
logical results are considered preliminary and, therefore, no
conclusion can be made concerning the mechanism of the
action. However, based on the comparison of the IC50 values
obtained on the two breast cancer cell lines, a receptor-inde-
pendent mechanism could be proposed. Results obtained for
the 2-bromo compounds (11a,b) reveal that bromination at this
position is disadvantageous concerning the antiproliferative
potential against the tested cell lines. However, the other
regioisomer without the 40-t-Bu group (12a), proved to be
highly potent with selective action against A2780 cells. The
dependence of the cell growth-inhibitory potential on the
regioisomerism is a very important structure–activity result.
Interestingly, the empirical rules established earlier proved to
be valid for the bromo derivatives (11a,b and 12a,b) as well.
The presence of the 40-t-Bu group on the newly introduced
benzylic moiety was also detrimental.
The cancer selectivity of compound 12a was tested by means
of the MTT assay using the non-cancerous mouse embryo fibro-
blast cell line NIH/3T3. The growth inhibitory effect was found to
be substantially lower than those against cancer cell lines. Since
the inhibition of proliferation was less than 40% even at the high-
est concentration (30 mM), the IC50 value was not calculated but it
is definitely above 30mM. This kind of viability assay cannot be
considered to be sufficient to declare a cancer-selective action.
The huge difference in the determined antiproliferative properties
may reflect a cell type-dependent action instead of a general toxic
character indicating the relevance of the presented structure in
lead-finding projects.
3.3. Tubulin polymerisation assay
Performing a 60-min-long tubulin polymerisation assay a direct
effect of 12a has been demonstrated on microtubule formation.
The significant increase in Vmax induced by our test compound is
similar to the effects of other oestrone derivatives from D-secoal-
cohol25 and D-secoestrone-triazole15 series. However, another ring
A substituted cytotoxic oestradiol analogue, 2-methoxyestradiol,
has been reported to inhibit tubulin polymerisation26. This result
is suitable for providing evidence about the final effect of our test
compound on tubulin-microtubule system.
3.4. Computational simulations
We have demonstrated earlier that core-modified oestrone deriva-
tive 3 might be considered as an MSA. However, the majority of
antitubulin oestrone derivatives described in literature belong to
the MDA group, acting at the CBS of tubulin. From the compari-
son of the structures of the brominated combrestatine triazole 2
as an MDA and oestrone derivative 3, it can be stated that they
possess similar structural elements, such as the two aryl systems
connected with a tetrazole or triazole bridge. It was shown by
Beale et al. that the presence of bromines in compound 2 is
advantageous concerning the antitubulin action. Interestingly, the
two compounds belong to different MT targeting groups. Here we
synthesised a new compound (12a) with structural similarity to
both MT targeting agents 2 and 3. Based on these structural
Figure 5. Best docking poses of compound 3 and 12a in the CBS of tubulin dimer. The dark blue structure represents compound 3, while purple marks com-
pound 12a.
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similarities and the substantial antiproliferative action of new
derivative 12a, here we performed computational studies to inves-
tigate the possible interaction of this compound with tubulin. Our
selection, concerning the potential binding region of compound
12a out of the known 6 possibilities7,10 taking tubulin surface,
was based on the following considerations. (i) Oestrone derivatives
usually interact with tubulin at the CBS11. (ii) Ligands which pro-
mote polymerisation of tubulin usually bind to the TBS7,8. Because
we did not have experimental evidence for the exact binding pos-
ition of compound 12a, both potential binding sites (CBS and
TBS) were considered. Secosteroid 3 was selected as a reference
compound and, altogether, four different complexes were investi-
gated in the simulations. Molecular docking studies were per-
formed first in order to get the best poses for the following MD
calculations. In Figures 5 and 6, we represented the binding poses
of ligands 3 and 12a in CBS and TBS, respectively. The purple
structure always represents compound 12a, while secoestrone 3 is
represented in dark blue. It is clear, that in the TBS both com-
pounds 3 and 12a adopted almost the same binding position,
while in the CBS the estrane cores occupied a common region,
but in a reverse manner. Consequently, the 3-N-benzyltriazolyl-
methyl moiety oriented in an opposite way in the two cases.
Concerning binding preference order, SP docking score only
helps to separate binding and non-binding molecules in a
molecular pocket. However, it is not suitable to determine an
accurate binding preference order; therefore, molecular dynamics
(MD) calculations were performed. This allowed us to calculate
binding energy at a more advanced level (MMGBSA method).
Furthermore, calculations also provide information about the sta-
bility of the binding pose concerning the different ligand–protein
complexes. It was established that the binding positions were sta-
ble in all four cases, even though the two compounds occupy the
CBS in reversed manner (Table 2). Comparing binding energies at
the same region, compound 12a had always stronger interaction
than compound 3. Comparing binding energies at the different
binding sites, compound 3 provided almost the same interaction
energies in the two binding pockets, while compound 12a had
stronger interaction at the TBS. The strong interactions of com-
pound 12a indicate that the hormonally inactive 13a-estrane core
with certain ring A modifications might be a suitable scaffold in
the design of potent MT targeting agents. Concerning its possible
dual binding (at CBS and at TBS), it might be a promising candi-
date in the development of antitubulin drugs targeting MDR
cells, too.
4. Materials and methods
4.1. Chemistry
Melting points (Mp) were determined with a Kofler hot-stage
apparatus and are uncorrected. Elemental analyses were per-
formed with a Perkin-Elmer CHN analyser model 2400
(PerkinElmer, Waltham, MA). Thin-layer chromatography: silica gel
60 F254; layer thickness 0.2mm (Merck); eluents (ss): A: 50% ethyl
acetate/50% hexane, B: ethyl acetate, C: 2% methanol/98% ethyl
acetate, detection with I2 or UV (365 nm) after spraying with 5%
phosphomolybdic acid in 50% aqueous phosphoric acid and heat-
ing at 100–120 C for 10min. Flash chromatography: silica gel 60,
40–63mm (Merck, Kenilworth, NJ). Reactions under microwave
irradiation were carried out with a CEM Corporation focussed
microwave system, Model Discover SP. The maximum power of
irradiation was 200W. 1H NMR spectra were recorded in DMSO-d6,
CDCl3 solution with a Bruker DRX-500 instrument (Bruker, Billerica,
MA) at 500MHz, with Me4Si as internal standard.
13C NMR spectra
were recorded with the same instrument at 125MHz under the
same conditions. Mass spectrometry: full scan mass spectra of the
compounds were acquired in the range of 50–1000m/z with a
Finnigan TSQ-7000 triple quadrupole mass spectrometer
(Finnigan-MAT, San Jose, CA) equipped with a Finnigan electro-
spray ionisation source. Analyses were performed in positive ion
mode using flow injection mass spectrometry with a mobile phase
of 50% aqueous acetonitrile containing 0.1 v/v% formic acid. The
flow rate was 0.3ml/min. Five ml aliquot of the samples were
loaded into the flow. The ESI capillary was adjusted to 4.5 kV and
N2 was used as a nebuliser gas.
4.1.1. Synthesis of 3-(prop-2-inyloxy)-13a-estra-1,3,5(10)-triene (10)
3-Hydroxy-13a-estra-1,3,5(10)-trien-17-one (1, 540mg, 2.0mmol)
was dissolved in acetone (15ml), then propargyl bromide [0.34ml
(80wt.% in toluene), 3.0mmol], and K2CO3 (1.94 g, 14mmol) were
added. The reaction mixture was stirred at 70 C for 24 h, the solv-
ent was then evaporated off, and the residue was purified by flash
chromatography with EtOAc/CH2Cl2 ¼ 2/98 as eluent. Compound
7 was obtained as a white solid (610mg, 98%), mp 133–134 C, Rf
¼ 0.70 (ss B); Anal calcd. for C21H24O2: C, 81.78; H, 7.84. Found: C,
81.93; H, 7.64. 1H NMR: d ppm H 1.06 (s, 3H, H-18); 2.49 (s, 1H,
CCH); 2.83 (m, 2H, H-6); 4.65 (s, 2H, OCH2); 6.68 (s, 1H, H-4); 6.77
(d, J¼ 8.5 Hz, 1H, H-2); 7.19 (d, J¼ 8.5 Hz, 1H, H-1). Compound 7 is
identical with the compound described in Ref. [16].
Figure 6. Best docking poses of compound 3 and 12a in the TBS of tubulin monomer. The dark blue structure represents compound 3 while purple marks com-
pound 12a.
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4.1.2. Synthesis of 3-[f1-benzyl-1H-1,2,3-triazol-4-ylgmethoxy]-
and 3-[f1-(4-tert-butylbenzyl)-1H-1,2,3-triazol-4-ylgmethoxy]-13a-
estra-1,3,5(10)-trien-17-one (4a and 4 b)
To a stirred solution of 3-(prop-2-inyloxy)-13a-estra-1,3,5(10)-trien-
17-one 7 (616mg, 2.0mmol) in toluene (8ml), Ph3P (52mg,
0.2mmol), CuI (19.0mg, 0.1mmol), DIPEA (1.04ml, 6.0mmol), and
benzylazide or 4-tert-butyl-benzylazide (1 equiv.16) were added.
The reaction mixtures were refluxed for 2 h, cooled to rt and
evaporated in vacuo. The residues were purified by flash chroma-
tography with EtOAc/CH2Cl2 ¼ 5/95 as eluent. Compound 4a was
obtained as a white solid (862mg, 97%), mp 164–165 C, Rf ¼ 0.35
(ss C); 1H NMR: d ppm 1.05 (s, 3H, H-18); 2.80 (m, 2H, H-6); 5.14 (s,
2H, OCH2); 5.51 (s, 2H, NCH2); 6.67 (s, 1H, H-4); 6.75 (dd, J¼ 8.5 Hz,
J¼ 2.0 Hz, 1H, H-2); 7.16 (d, J¼ 8.5 Hz, 1H, H-1); 7.27 (m, 2H, H-20,
H-60); 7.36 (m, 3H, H-30, H-40, H-50); 7.50 (s, 1H, C¼CH). Compound
4a is identical with the compound described in Ref. [16].
Compound 4b was obtained as a white solid (961mg, 96%),
mp 111–112 C, Rf ¼ 0.28 (ss C); 1H NMR: d ppm 1.05 (s, 3H, H-18);
1.31 (s, 3 3H, C(CH3)3); 2.81 (m, 2H, H-6); 5.11 (s, 2H, OCH2); 5.50
(s, 2H, NCH2); 6.69 (s, 1H, H-4); 6.78 (m, 1H, H-2); 7.16–7.20 (over-
lapping multiplets, 3H, H-1, H-20, H-60); 7.39 (d, 2H, H-30, H-50); 7.55
(s, 1H, C¼CH). Compound 4a is identical with the compound
described in Ref. [16].
4.1.3. General procedure for the bromination of triazoles 4a
and 4b
Triazole 4a or 4b (442mg or 498mg, 1.00mmol) was dissolved in
dichloromethane (5ml) and NBS (178mg, 1.00mmol) was added.
The mixture was stirred at rt for 2.5 h, the solvent was then evapo-
rated off and the crude product was purified by flash chromatog-
raphy with EtOAc/hexane ¼ 30/70 as eluent.
4.1.3.1. Synthesis of 3-[f1-benzyl-1H-1,2,3-triazol-4-ylgmethoxy]-2-
bromo-13a-estra-1,3,5(10)-trien-17-one (11a) and 3-[f1-benzyl-1H-
1,2,3-triazol-4-ylgmethoxy]-4-bromo-13a-estra-1,3,5(10)-trien-17-
one (12a). The first-eluting 12a was obtained as a white solid
(160mg, 31%). Mp.: 188–190 C. Rf¼0.66 (ss A). Anal calcd. for
C28H30BrN3O2: C, 64.26; H, 5.81. Found: C, 64.34; H, 5.89.
1H NMR
(CDCl3) d ppm: 1.05 (s, 3H, H-18), 2.65 and 3.00 (2m, 2 1H, H-
6), 5.24 (m, 2H, OCH2), 5.52 (s, 2H, NCH2), 6.87 (d, J¼ 8.6 Hz, 1H, H-
2), 7.19 (d, J¼ 8.6, 1H, H-1), 7.27–7.28 (overlapping multiplets, 2H,
H-20 and H-60), 7.34–7.37 (overlapping multiplets, 3H, H-30, H-40
and H-60), 7.58 (s, 1H, C ¼ CH). 13C NMR (CDCl3) d ppm: 21.0
(CH2), 25.0 (C-18), 28.3 (CH2), 28.4 (CH2), 31.6 (CH2), 31.9 (CH2),
33.4 (CH2), 40.6 (CH), 41.7 (CH), 49.0 (CH), 50.0 (C-13), 54.2 (NCH2),
63.7 (OCH2), 111.4 (C-2), 115.2 (C-4), 122.7 (C ¼ CH), 125.5 (C-1),
128.0 (2 C, C-30 and C-50), 128.8 (C-40), 129.1 (2 C, C-20 and C-60),
134.5 (C-10), 134.9 (C-10), 137.9 (C-5), 144.7 (C ¼ CH),152.6 (C-3),
221.4 (C-17). MS: [MþH]þ (79/81Br) 519 and 521.
The next-eluting 11a was obtained as a white solid (319mg,
61%). Mp.: 151–154 C. Rf¼0.54 (ss A). Anal calcd. for
C28H30BrN3O2: C, 64.26; H, 5.81. Found: 64.36; H, 5.88.
1H NMR
(CDCl3) d ppm: 1.05 (s, 3H, H-18), 2.70–2.82 (overlapping multip-
lets, 2H, H-6), 5.26 (m, 2H, OCH2), 5.55 (s, 2H, NCH2), 6.72 (s, 1H, H-
4), 7.27–7.29 (overlapping multiplets, 2H, H-20, and H-60), 7.38–7.39
(overlapping multiplets, 3H, H-30, H-40, H-60), 7.66 (s, 1H, C ¼ CH).
13C NMR (CDCl3) d ppm: 20.9 (CH2), 25.0 (C-18), 28.0 (CH2), 28.2
(CH2), 30.0 (CH2), 31.9 (CH2), 33.4 (CH2), 41.1 (CH), 41.3 (CH), 49.1
(CH), 50.1 (C-13), 54.8 (NCH2), 63.1 (OCH2), 109.4 (C-2), 114.3 (C-4),
123.2 (C¼CH), 128.2 (2 C, C-30, and C-50), 129.1 (C-40), 129.2 (2 C, C-
20, and C-60), 130.8 (C-1), 133.8 (C-10), 134.7 (C-10), 137.6 (C-5),
144.1 (C¼CH), 152.1 (C-3), 221.4 (C-17). MS m/z (%): MS: [MþH]þ
(79/81Br) 519 and 521.
4.1.3.2. Synthesis of 2-bromo-3-[f1–(4-tert-butylbenzyl)-1H-1,2,3-
triazol-4-ylgmethoxy]-13a-estra-1,3,5(10)-trien-17-one (11 b) and
4-bromo-3-[f1–(4-tert-butylbenzyl)-1H-1,2,3-triazol-4-ylgmethoxy]-
13a-estra-1,3,5(10)-trien-17-one (12 b). The first-eluting 12b was
obtained as a white solid (98mg, 17%). Mp.: 178–180 C. Rf¼0.71
(ss A). Anal calcd. for C32H38BrN3O2: C, 66.66; H, 6.64. Found:
66.73; H, 6.72. 1H NMR (CDCl3) d ppm: 1.05 (s, 3H, H-18), 1.31 (s,
9H, 40-C(CH3)3), 2.65 and 3.00 (2m, 2 1H, H-6), 5.23 (m, 2H,
OCH2), 5.49 (s, 2H, NCH2), 6.87 (d, J¼ 8.7 Hz, H-2), 7.18 (d,
J¼ 8.7 Hz, 1H, H-1), 7.20 (d, J¼ 8.4 Hz, 2H, H-20, and H-60), 7.38 (d,
J¼ 8.4 Hz, 2H, H-30, and H-50), 7.58 (s, 1H, C¼CH). 13C NMR
(CDCl3) d ppm: 21.0 (CH2), 25.0 (C-18), 28.3 (CH2), 28.4 (CH2), 31.2
(3 C, 40-C(CH3)3), 31.6 (CH2), 31.9 (CH2), 33.4 (CH2), 34.6 (40-C(CH3)3),
40.6 (CH), 41.7 (CH), 49.0 (CH), 50.0 (C-13), 53.9 (NCH2), 63.6
(OCH2), 111.4 (C-2), 115.2 (C-4), 122.6 (C¼CH), 125.5 (C-1), 126.0
(2 C, C-30, and C-50), 127.8 (2 C, C-20, and C-60), 131.5 (C-10), 134.9
(C-10), 137.9 (C-5), 144.6 (C¼CH), 151.9 and 152.6 (2 C, C-3, and C-
40), 221.4 (C-17). MS: [MþH]þ (79/81Br) 575 and 577. Continued
elution yielded first a mixture of 12b (80mg, 14%) and 11b
(140mg, 24%), and then compound 11b (218mg, 38%) as a white
solid. Mp.: 148–150 C. Rf¼0.62 (ss A). Anal calcd. for
C32H38BrN3O2: C, 66.66; H, 6.64. Found: 64.72; H, 6.72.
1H NMR
(CDCl3) d ppm: 1.05 (s, 3H, H-18), 1.37 (s, 9H, 40-C(CH3)3), 2.70–2.82
(overlapping multiplets 2H, H-6), 5.22 (m, 2H, OCH2), 5.49 (s, 2H,
NCH2), 6.74 (s, 1H, H-4), 7.20 (d, J¼ 8.4 Hz, 2H, H-20, and H-60),
7.37–7.39 (overlapping multiplets, 3H, H-30, H-50, and H-1), 7.58 (s,
1H, C¼CH). 13C NMR (CDCl3) d ppm: 20.9 (CH2), 25.0 (C-18), 28.0
(CH2), 28.2 (CH2), 30.0 (CH2), 31.2 (40-C(CH3)3), 31.9 (CH2), 33.4 (C),
34.6 (40-C(CH3)3), 41.1 (CH), 41.3 (CH), 49.1 (CH), 50.0 (C-13), 53.9
(NCH2), 63.7 (OCH2), 109.5 (C-2), 114.3 (C-4), 122.6 (C¼CH), 126.0
(2 C, C-30, and C-50), 127.8 (2 C, C-20, and C-60), 130.7 (C-1), 131.4
(C-10), 134.4 (C-10), 137.4 (C-5), 144.6 (C¼CH), 151.9 and 152.4 (2 C,
C-3, and C-40), 221.3 (C-17). MS: [MþH]þ (79/81Br) 575 and 577.
4.1.4. General procedure for Hirao coupling of brominated tria-
zoles (11a,b and 12a,b)
2- or 4-Bromo triazoles (11a,b or 12a,b; 260mg or 288mg,
0.50mmol), tetrakis(triphenylphosphine)palladium(0) (57.8mg,
0.050mmol, 10mol%), potassium carbonate (104mg, 0.75mmol,
1.5 equiv.), diethyl phosphite (0.50mmol, 69mg) or diphenylphos-
phine oxide (0.50mmol, 101mg), and acetonitrile or toluene (5ml)
were added into a 10ml Pyrex pressure vessel (CEM, Part #:
908035) with silicone cap (CEM, Part #: 909210). The mixture was
irradiated in a CEM microwave reactor at 150 C 30–60min under
stirring. The solvent was evaporated in vacuo and the residue was
purified by flash chromatography.
4.1.4.1. Synthesis of (3-[f1-benzyl-1H-1,2,3-triazol-4-ylgmethoxy]-
13a-estra-1,3,5(10)-trien-17-on-2-yl)-diethylphosphonate. The resi-
due was purified by flash chromatography with MeOH/EtOAc ¼ 2/
98 as eluent. Compound 13a was isolated as a white solid (84%).
Mp.: 75–80 C. Rf¼0.31 (ss B). Anal calcd. for C32H40N3O5P: C,
66.54; H, 6.98. Found: 66.62; H, 7.07. 1H NMR (CDCl3) d ppm: 1.05
(s, 3H, H-18), 1.16 (t, J¼ 7.1 Hz, 6H, 2OCH2CH3), 2.85 (m, 2H, H-
6), 3.93–4.03 (overlapping multiplets, 4H, 2OCH2CH3), 5.25 (m,
2H, OCH2), 5.53 (s, 2H, NCH2), 6.73 (d, J¼ 6.8 Hz, 1H, H-4), 7.27 (m.
2H, H-20, and H-60), 7.39 (overlapping multiplets, 3H, H-30, H-4’and
H-50), 7.66 (d, J¼ 15.7 Hz, H-1), 7.83 (s, 1H, C¼CH). 13C NMR
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(CDCl3) d ppm: 16.3 (d, J¼ 6.3 Hz, 2 C: 2OCH2CH3), 20.9 (CH2),
25.0 (C-18), 27.8 (CH2), 28.2 (CH2), 30.6 (CH2), 31.8 (CH2), 33.3
(CH2), 41.2 (CH), 41.3 (CH), 49.1 (CH), 50.1 (C-13), 54.3 (NCH2), 61.9
(2 C, 2OCH2CH3), 63.1 (OCH2), 112.8 (d, J¼ 9.9 Hz, C-4), 114.1 (d,
J¼ 188.9 Hz, C-2), 123.1 (C¼CH), 128.1 (2 C, C-30, and C-50), 128.7
(C-40), 129.1 (2 C, C-20, and C-60), 132.6 (d, J¼ 13.8 Hz, C-10), 132.8
(d, J¼ 8.1 Hz, C-1), 134.5 (C-10), 144.0 (2 C, C-5, and C¼CH), 157.4
(C-3), 221.4 (C-17). 31 P NMR d ppm: 17.8. MS m/z (%): 578
(100, [MþH]þ).
4.1.4.2. Synthesis of (3-[f1–(4-tert-butylbenzyl)-1H-1,2,3-triazol-4-
ylgmethoxy]-13a-estra-1,3,5(10)-trien-17-on-2-yl)-diethylphospho-
nate. The residue was purified by flash chromatography with
MeOH/EtOAc ¼ 2/98 as eluent. Compound 13b was isolated as a
colourless oil (83%). Rf¼0.55 (ss B). Anal calcd. for C36H48N3O5P: C,
68.23; H, 7.63. Found: 68.31; H, 7.72. 1H NMR (CDCl3) d ppm: 1.05
(s, 3H, H-18), 1.15 (t, J¼ 7.1 Hz, 6H, 2OCH2CH3), 1.29 (s, 9H, 40-
C(CH3)3), 2.85 (m, 2H, H-6), 3.92–4.03 (overlapping multiplets, 4H,
2OCH2CH3), 5.23 (m, 2H, OCH2), 5.48 (s, 2H, NCH2), 6.73 (d,
J¼ 6.9 Hz, 1H, H-4), 7.21 (d, J¼ 8.4 Hz, 2H, H-20, and H-60), 7.37 (d,
J¼ 8.4 Hz, 2H, H-30, and H-50), 7.67 (d, J¼ 15.7 Hz, 1H, H-1), 7.77 (s,
1H, C¼CH). 13C NMR (CDCl3) d (ppm): 16.3 (d, J¼ 6.6 Hz, 2 C,
2OCH2CH3), 20.9 (CH2), 25.0 (C-18), 27.8 (CH2), 28.2 (CH2), 30.6
(CH2), 31.2 (3 C, 40-C(CH3)3), 31.9 (CH2), 33.3 (CH2), 34.6 (40-C(CH3)3),
41.2 (CH), 41.3 (CH), 49.1 (CH), 50.0 (C-13), 53.9 (NCH2), 61.8 (2 C,
2OCH2CH3), 63.2 (OCH2), 112.7 (d, J¼ 9.8 Hz, C-4), 114.1 (d,
J¼ 189.4 Hz, C-2), 122.8 (C¼CH), 125.9 (2 C, C-30, and C-50), 127.8
(2 C, C-20, and C-60), 131.6 (C-10), 132.6 (d, J¼ 14.1 Hz, C-10), 132.9
(d, J¼ 7.9 Hz, C-1), 143.9 and 144.9 (2 C, C-5, and C¼CH), 151.8 (C-
40), 157.5 (C-3), 221.3 (C-17). 31P NMR d ppm 17.8. MS m/z (%):
634 (100, [MþH]þ).
4.1.4.3. Synthesis of (3-[f1-benzyl-1H-1,2,3-triazol-4-ylgmethoxy]-
13a-estra-1,3,5(10)-trien-17-on-2-yl)diphenylphosphine oxide. The
residue was purified by flash chromatography with MeOH/EtOAc
¼ 2/98 as eluent. Compound 14a was isolated as a white solid
(79%). Mp.: 117–120 C. Rf¼0.28 (ss C). Anal calcd. for
C40H40N3O3P: C, 74.86; H, 6.28. Found: 74.93; H, 6.33.
1H NMR
(CDCl3) d ppm: 1.03 (s, 3H, H-18), 2.87 (m, 2H, H-6), 5.00 (m, 2H,
OCH2), 5.38 (s, 2H, NCH2), 6.72–6.73 (overlapping multiplets, 2H),
7.15–7.17 (overlapping multiplets, 2H), 7.24–7.30 (m, 2H),
7.34–7.41 (overlapping multiplets, 6H), 7.55–7.63 (overlapping mul-
tiplets, 6H). 13C NMR (CDCl3) d ppm: 20.9 (CH2), 25.0 (C-18), 27.9
(CH2), 28.1 (CH2), 30.7 (CH2), 31.8 (CH2), 33.4 (CH2), 41.3 (CH), 41.5
(CH), 49.2 (CH), 50.1 (C-13), 54.0 (NCH2), 62.5 (OCH2), 112.4 (d,
J¼ 6.9 Hz, C-4), 117.6 (d, J¼ 105.5 Hz, C-2), 122.6 (C¼CH), 127.9
(2 C, C-30, and C-50), 128.0–128.2 (overlapping multiplets, 4 C),
128.7 (C-40), 129.1 (2 C, C-20, and C-60), 131.3 (m, 2 C, C-4” , and C-
40”), 131.6–131.8 (overlapping multiplets, 4 C), 132.6 (C), 132.9 (d,
J¼ 7.5 Hz, C-1), 133.0 (C), 133.5 (C), 134.7 (C), 143.9 (C), 144.1 (C),
157.1 (C-3), 221.2 (C-17). 31P NMR d ppm: 27.2. MS m/z (%): 642
(100, [MþH]þ).
4.1.4.4. Synthesis of (3-[f1–(4-tert-butylbenzyl)-1H-1,2,3-triazol-4-
ylgmethoxy]-13a-estra-1,3,5(10)-trien-17-on-2-yl)diphenylphos-
phine oxide. The residue was purified by flash chromatography
with MeOH/EtOAc ¼ 2/98 as an eluent. Compound 14b was iso-
lated as a white solid (73%). Mp.: 205–208 C. Rf¼0.42 (ss C). Anal
calcd. for C44H48N3O3P: C, 75.73; H, 6.93. Found: 75.79; H, 6.99.
1H
NMR (CDCl3) d ppm: 1.03 (s, 3H, H-18), 1.31 (s, 9H, 40-C(CH3)3), 2.87
(m, 2H, H-6), 5.00 (d, J¼ 4.0 Hz, 2H, OCH2), 5.38 (s, 2H, NCH2), 6.61
(s, 1H, C¼CH), 6.71 (d, J¼ 5.5 Hz, 1H, H-4), 7.09 (d, 2H), 7.21 (m,
2H), 7.27 (m, 2H), 7.33–7.40 (overlapping multiplets, 4H), 7.54–7.62
(overlapping multiplets, 4H), 7.64 (d, J¼ 14.2 Hz, 1H, H-1). 13C
NMR (CDCl3) d ppm: 20.9 (CH2), 25.0 (C-18), 27.9 (CH2), 28.1 (CH2),
30.7 (CH2), 31.2 (3 C, 40-C(CH3)3), 31.8 (CH2), 33.4 (CH2), 34.6 (40-
C(CH3)3), 41.3 (CH), 41.4 (CH), 49.1 (CH), 50.1 (C-13), 53.7 (NCH2),
62.3 (OCH2), 112.2 (d, J¼ 7.1 Hz, C-4), 117.5 (d, J¼ 105.6 Hz, C-2),
122.4 (C¼CH), 125.9 (2 C, C-30, and C-50), 127.7 (2 C, C-20, and C-60),
127.9–128.1 (overlapping multiplets, 4 C), 131.2 and 131.3 (C-4”
and C-40”), 131.6–131.8 (overlapping multiplets, 4 C), 131.6–134.0
(overlapping multiplets, 4 C), 132.9 (d, J¼ 7.6 Hz, C-1), 143.9 and
144.0 (C-5 and C¼CH), 151.9 (C-40), 156.9 (d, J¼ 3.0 Hz, C-3), 221.4
(C-17). 31 P NMR d ppm: 26.9. MS m/z (%): 698 (100, [MþH]þ).
4.1.4.5. Synthesis of (3-[f1-benzyl-1H-1,2,3-triazol-4-ylgmethoxy]-
13a-estra-1,3,5(10)-trien-17-on-4-yl)-diethylphosphonate. The resi-
due was purified by flash chromatography with MeOH/EtOAc ¼ 2/
98 as an eluent. Compound 15a was isolated as a white solid
(72%). Mp.: 43–45 C. Rf¼0.45 (ss B). Anal calcd. for C32H40N3O5P:
C, 66.54; H, 6.98. Found: C, 66.62; H, 7.07. 1H NMR (CDCl3) d
(ppm): 1.05 (s, 3H, H-18), 1.13 (t, J¼ 7.2 Hz, 6H, 2OCH2CH3), 3.26
(m, 2H, H-6), 3.88–4.01 (overlapping multiplets, 4H, 2OCH2CH3),
5.21 (d, J¼ 3.8 Hz, 2H, OCH2), 5.53 (s, 2H, NCH2), 6.87 (dd,
J¼ 6.7 Hz, J¼ 8.4 Hz, 1H, H-2), 7.26–7.28 (m, 2H, H-20, and H-60),
7.33–7.38 (overlapping multiplets, 2H, H-30, H-40, H-50, and H-1),
7.72 (s, 1H, C¼CH). 13C NMR (CDCl3) d (ppm): 16.2 (2 C,
2OCH2CH3), 20.9 (CH2), 24.9 (C-18), 28.2 (CH2), 28.6 (CH2), 29.3
(CH2), 32.0 (CH2), 33.3 (CH2), 40.3 (CH), 41.7 (CH), 49.5 (CH), 50.1
(C-13), 54.2 (NCH2), 61.3 (d, J¼ 5.2 Hz, OCH2CH3), 61.4 (d,
J¼ 5.2 Hz, OCH2CH3), 63.7 (OCH2), 110.9 (d, J¼ 10.1Hz, C-2), 115.1
(d, J¼ 182.0 Hz, C-4), 122.8 (C¼CH), 128.1 (2 C, C-30, and C-50),
128.7 (C-40), 129.1 (2 C, C-20, and C-60), 131.5 (C-1), 134.4 (d,
J¼ 14.0 Hz, C-10), 134.6 (C-10), 144.8 (d, J¼ 10.0 Hz, C-5), 144.8
(C¼CH), 145.0 (C), 159.0 (C-3), 221.6 (C-17). 31P NMR d (ppm): 18.2.
MS m/z (%): 578 (100, [MþH]þ).
4.1.4.6. Synthesis of (3-[f1–(4-tert-butylbenzyl)-1H-1,2,3-triazol-4-
ylgmethoxy]-13a-estra-1,3,5(10)-trien-17-on-4-yl)-diethylphospho-
nate. The residue was purified by flash chromatography with
EtOAc as an eluent. Compound 15b was obtained as a white solid
(70%). Mp.: 54–59 C. Rf¼0.51 (ss B). Anal calcd. for C36H48N3O5P:
C, 68.26; H, 7.63. Found: C, 68.34; H, 7.69. 1H NMR (CDCl3) d (ppm)
1.05 (s, 3H, H-18), 1.11 (t, J¼ 7.1 Hz, 6H, 2OCH2CH3), 1.29 (s, 9H,
40-C(CH3)3), 3.25 (m, 2H, H-6), 3.88–4.01 (overlapping multiplets,
4H, 2OCH2CH3), 5.20 (d, J¼ 3.9 Hz, 2H, OCH2), 5.49 (s, 2H, NCH2),
6.87 (dd, J¼ 6.6 Hz, J¼ 8.6 Hz, 1H, 2-H), 7.21 (d, J¼ 8.2 Hz, 2H, H-30,
and H-50), 7.37 (overlapping multiplets, 3H, H-20, H-60, and H-1),
7.71 (s, 1H, C¼CH). 13C NMR (CDCl3) d (ppm): 16.2 (d, J¼ 6.6 Hz,
2 C, 2OCH2CH3), 20.9 (CH2), 24.9 (C-18), 28.1 (CH2), 28.6 (CH2),
29.3 (CH2), 31.2 (3 C, 40-C(CH3)3), 31.9 (CH2), 33.3 (CH2), 34.6 (40-
C(CH3)3), 40.3 (CH), 41.7 (CH), 49.4 (CH), 50.1 (C-13), 53.9 (NCH2),
61.2 (d, J¼ 5.4 Hz, OCH2CH3), 61.4 (d, J¼ 5.4 Hz, OCH2CH3), 63.6
(OCH2), 110.8 (d, J¼ 9.9 Hz, C-2), 114.9 (d, J¼ 182.5 Hz, C-4), 122.7
(C¼CH), 126.0 (2 C, C-30, and C-50), 127.9 (2 C, C-20, and C-60), 131.4
(d, J¼ 1.8 Hz, C-1), 131.5 (C-10), 134.4 (d, J¼ 14.4 Hz, C-10), 144.7
and 144.8 (C¼CH and C-5), 151.9 (C-40), 158.9 (C-3), 221.6 (C-17).
31 P NMR d (ppm): 18.2. MS m/z (%): 634 (100, [MþH]þ).
4.2. Determination of antiproliferative activities
The antiproliferative properties of the newly synthesised triazoles
(11a,b–15a,b) were determined on a panel of human adherent
cancer cell lines of gynaecological origin. MCF-7 and MDA-MB-231
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were isolated from breast cancers differing in biochemical back-
ground, while A2780 cells were isolated from ovarian cancer. The
cancer selectivity of compound 12a was tested on the non-can-
cerous mouse embryo fibroblast cell line NIH/3T3. All cell lines
were purchased from European Collection of Cell Cultures (ECCAC,
Salisbury, UK). Cells were cultivated in minimal essential medium
supplemented with 10% foetal bovine serum, 1% non-essential
amino acids and an antibiotic–antimycotic mixture. All media and
supplements were obtained from Lonza Group Ltd., Basel,
Switzerland. Near-confluent cancer cells were seeded onto a 96-
well microplate (5000 cells/well) and, after overnight standing,
200 mL new medium, containing the tested compounds at 10 and
30mM, was added. After incubation for 72 h at 37 C in humidified
air containing 5% CO2, the living cells were assayed by the add-
ition of 20mL of 5mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) solution. MTT was converted by intact
mitochondrial reductase and precipitated as purple crystals during
a 4-h contact period. The medium was next removed and the pre-
cipitated formazan crystals were dissolved in 100 mL of DMSO dur-
ing a 60-min period of shaking at 37 jC.
Finally, the reduced MTT was assayed at 545 nm, using a micro-
plate reader utilising wells with untreated cells serving as con-
trol27. In the case of the most active compounds (i.e. higher than
50% growth inhibition at 30mM), the assays were repeated with a
set of dilutions, sigmoidal dose–response curves were fitted to the
determined data and the IC50 values (the concentration at which
the extent of cell proliferation was half that of the untreated con-
trol) were calculated by means of GraphPad Prism 4.0 (GraphPad
Software, San Diego, CA). All in vitro experiments were carried out
on two microplates with at least five parallel wells. Stock solutions
of the tested substances (10mM) were prepared in DMSO. The
highest DMSO content of the medium (0.3%) did not have any
substantial effect on cell proliferation. Cisplatin (Ebewe Pharma
GmbH, Unterach, Austria) was used as positive control.
4.3. Tubulin polymerisation assay
The effect of brominated triazole (12a) on tubulin polymerisation
was tested with the HTS-Tubulin Polymerisation Assay Biochem Kit
(Bio-Kasztel Ltd., Budapest, Hungary) according to the manufac-
turer’s recommendations. Briefly, 10ml of a 0.125 or 0.25mM solu-
tion of the test compound (12a) was placed on a prewarmed
(37 C), UV-transparent microplate. About 10ml 10 mM paclitaxel
and 10 ml General Tubulin Buffer were used as positive and nega-
tive control, respectively. 100 ml 3.0mg/ml tubulin in 80mM PIPES
pH 6.9, 2mM MgCl2, 0.5mM EGTA, 1mM GTP was added to each
sample, and the microplate was immediately placed into a pre-
warmed (37 C) UV-spectrophotometer (SpectoStarNano, BMG
Labtech, Ortenberg, Germany) to start the recording reaction. A
60-min kinetic measurement protocol was applied to determine
the absorbance of the reaction solution per minute at 340 nm. For
the evaluation of the experimental data, the maximum reaction
rate (Vmax: Dabsorbance/min) was calculated. Moving averages of
absorbances determined at three consecutive timepoints were cal-
culated and the highest difference between two succeeding mov-
ing averages was taken as the Vmax of the tested compound in
the tubulin polymerisation reaction. Each sample was prepared in
two parallels and the measurements were repeated twice. For
statistical evaluation, Vmax data were analysed by the one-way
ANOVA test with the Newmann–Keuls post-test by using Prism
4.01 software (GraphPad Software, San Diego, CA).
4.4. Computational simulations
4.4.1. Docking studies
In all cases, the Glide package28,29 of the Schrodinger suit30 was
applied for docking calculations. Dimer structure with a colchicine
analogue was cut out from crystal structure (pdb id: 3HKC, www.
rcsb.org31) for colchicine binding side studies, and a monomer
unit in complex with taxol was taken from taxol-stabilized micro-
tubule (pdb id: 5SYF).
The protein preparation wizard32 was applied in the Maestro
GUI33 for the preparation of the downloaded rough crystal struc-
tures, and docking grids were prepared first. Each grid was cen-
tred to the original crystal ligand position, and default box size
was applied. Following the grid generation, single precision (SP)
docking was performed with enhanced ligand sampling. In the
output, five poses were written out for each ligand.
4.4.2. Molecular dynamics calculations
The MD calculations were carried out with the Desmond34,35 pro-
gram of the Schrodinger suit. OPLS3e forcefield36 in combination
with SPC explicit water model was applied in physiological salt
concentration. Orthorhombic box with 10Å buffer size was set up,
and single strand 250 ns long NPT MD running was performed at
310 K after the relaxation of the system. The Nose–Hoover37
thermostat and Martyna–Tobias–Klein barostat were applied with
default relaxation times. The MMGBSA interaction energies were
determined by taking 250 snapshots periodically from the MD tra-
jectories and the thermal_mmgbsa.py script of the Desmond pro-
gram was applied to calculate the binding free energy of a ligand.
5. Conclusions
In conclusion, new ring A modified 13a-oestrone derivatives have
been synthesised via directed combination of different structural
elements. Certain new compounds displayed potent antiprolifera-
tive action against human reproductive cancer cell lines. 4-Bromo
derivative 12a exerted submicromolar cell growth-inhibitory
action against A2780 cell line. Computational simulations reveal
strong interactions of compound 12a with colchicine and taxoid
binding sites of tubulin. Direct effect of compound 12a on micro-
tubule formation was demonstrated via tubulin polymerisa-
tion assay.
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